Guan, Ye
Ly, Neang
Li, Jing
Arends, Rosalinda H.
Article History
Accepted: 14 November 2021
First Online: 2 March 2022
Declarations
:
: This study was funded by AstraZeneca.
: Rosalinda H. Arends is an employee of AstraZeneca and owns stock in AstraZeneca. Ye Guan, Neang Ly, and Jing Li were employees of AstraZeneca. Neang Ly and Jing Li owned stock in AstraZeneca at the time the study was conducted.
: All studies were conducted in accordance with the principles in the Declaration of Helsinki. Clinical protocols were reviewed and approved for each site by institutional review boards.
: All subjects enrolled provided written informed consent prior to participation in the studies.
: Not applicable.
: Not applicable.
: No data have been shared.
: YG and JL wrote the manuscript. YG, NL, and JL designed and conducted the pharmacometric analysis. YG, NL, JL, and RA contributed to data acquisition and interpretation. All authors revised the manuscript and accepted its form for submission. This work focuses on population pharmacokinetic modeling using pooled data from six clinical trials, which involves multiple principal investigators across different countries. As the principal investigators of the clinical trials did not participate in the modeling analysis work, they are not included as authors on this paper. However, Lars Hansen, MD, PhD, (Early Clinical Development, AstraZeneca) oversees the clinical aspects for the cotadutide program including the current analysis.